Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corrona Psoriasis (PSO) Registry

Next Previous
Trial Profile

Corrona Psoriasis (PSO) Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Apremilast (Primary) ; Brodalumab (Primary) ; Ciclosporin (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Methotrexate (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary)
  • Indications Plaque psoriasis; Psoriasis
  • Focus Adverse reactions

    • Most Recent Events

    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 13 Sep 2018 According to a Novartis media release, data from the study evaluating Cosentyx, has been presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress 2018.
    • 16 Oct 2017 Results (n=1942, Data cut off October 31, 2016) of cross sectional study published in the Journal of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top